Author

Rhys Williams

Institution: BeOne Medicines (Switzerland)

Observed institution: BeOne Medicines (Switzerland)

OpenAlex ID: A5138440567

Real-World Outcomes Among Medicare Beneficiaries Treated with Bruton Tyrosine Kinase Inhibitors for Treatment-Naïve CLL

2026 · Daniel A. Ermann, Deborah M. Stephens, et al. · Oncology and Therapy

Indirect Comparison of the Efficacy of Zanubrutinib vs Ibrutinib and Acalabrutinib in Treatment-Naive Chronic Lymphocytic Leukemia: 6-Year Follow-Up

2026 · Mazyar Shadman, Talha Munir, et al. · Advances in Therapy

A real-world comparison of treatment and survival outcomes with zanubrutinib (zanu) and acalabrutinib (acala) monotherapy among patients with relapsed or refractory (R/R) mantle cell lymphoma (MCL) in the United States.

2026 · Yucai Wang, Manasi Suryavanshi, et al. · Journal of Clinical Oncology

Real-world treatment and survival outcomes for zanubrutinib (zanu) and acalabrutinib (acala) monotherapy among treatment-naive patients with chronic lymphocytic leukemia (CLL) in the United States.

2026 · Ryan Jacobs, Manasi Suryavanshi, et al. · Journal of Clinical Oncology

Works count: 4

Citation count:

H-index:

I10-index: